DK182081A - Fremgangsmaade til fremstilling af hydroxaminsyrer - Google Patents

Fremgangsmaade til fremstilling af hydroxaminsyrer

Info

Publication number
DK182081A
DK182081A DK182081A DK182081A DK182081A DK 182081 A DK182081 A DK 182081A DK 182081 A DK182081 A DK 182081A DK 182081 A DK182081 A DK 182081A DK 182081 A DK182081 A DK 182081A
Authority
DK
Denmark
Prior art keywords
chem
topical
carbamyl
inflammatory
residue
Prior art date
Application number
DK182081A
Other languages
English (en)
Other versions
DK156717B (da
DK156717C (da
Inventor
K B Sloan
R Little
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK182081A publication Critical patent/DK182081A/da
Publication of DK156717B publication Critical patent/DK156717B/da
Application granted granted Critical
Publication of DK156717C publication Critical patent/DK156717C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK182081A 1980-04-24 1981-04-23 Analogifremgangsmaade til fremstilling af indomethacinderivater DK156717C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14352080A 1980-04-24 1980-04-24
US14352080 1980-04-24

Publications (3)

Publication Number Publication Date
DK182081A true DK182081A (da) 1981-10-25
DK156717B DK156717B (da) 1989-09-25
DK156717C DK156717C (da) 1990-02-19

Family

ID=22504442

Family Applications (1)

Application Number Title Priority Date Filing Date
DK182081A DK156717C (da) 1980-04-24 1981-04-23 Analogifremgangsmaade til fremstilling af indomethacinderivater

Country Status (9)

Country Link
EP (1) EP0039051B1 (da)
JP (1) JPS56167643A (da)
AT (1) ATE14423T1 (da)
DE (1) DE3171467D1 (da)
DK (1) DK156717C (da)
ES (1) ES501573A0 (da)
GR (1) GR74496B (da)
IE (1) IE53001B1 (da)
PT (1) PT72878B (da)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
US5068251A (en) * 1988-12-16 1991-11-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US5212189A (en) * 1991-12-17 1993-05-18 Warner-Lambert Company Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
ES2355472T3 (es) 2002-05-22 2011-03-28 Amgen Inc. Derivados de aminopirimidina para su uso como ligandos del receptor vaniloide para el tratamiento del dolor.
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
TW200410945A (en) 2002-08-08 2004-07-01 Amgen Inc Vanilloid receptor ligands and their use in treatments"
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7429616B2 (en) 2005-07-15 2008-09-30 Board Of Regents, University Of Texas System Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
KR20080104347A (ko) 2006-03-29 2008-12-02 노파르티스 아게 선택적 히드록사메이트-기재 ｍｍｐ 억제제
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
EP2049115B1 (en) 2006-07-14 2013-08-21 Amgen Inc. Alkyne-substituted pyridone compounds and methods of use
CA2658190C (en) 2006-07-20 2013-01-29 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
HUE028954T2 (en) 2007-03-23 2017-01-30 Amgen Inc Heterocyclic compounds and their use
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
US8759365B2 (en) 2007-12-03 2014-06-24 Novartis Ag Organic compounds
ES2524259T3 (es) 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
AU2009333214B2 (en) 2008-12-17 2013-09-26 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010075869A1 (en) 2008-12-30 2010-07-08 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use
WO2010085968A1 (en) 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
PE20120403A1 (es) 2009-05-15 2012-05-03 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
MX2011013510A (es) 2009-06-25 2012-03-07 Amgen Inc Compuestos heterociclicos y sus usos.
MX2011013667A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
CA2765823A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Tricyclic heterocyclic compounds as mediators of p13k activity
AR077328A1 (es) 2009-07-24 2011-08-17 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CA2772625A1 (en) 2009-09-03 2011-03-10 Allergan, Inc. Compounds as tyrosine kinase modulators
CA2771563A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
BR112012008147A2 (pt) 2009-09-04 2016-03-01 Novartis Ag compostos heteroarílicos como inibidores da quinase
IN2012DN01273A (da) 2009-09-04 2015-05-15 Novartis Ag
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
EP2513109A1 (en) 2009-12-18 2012-10-24 Amgen Inc. Heterocyclic compounds and their uses
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
EP2516439B1 (en) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undecanes as orexin receptor antagonists
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
EP2569306A1 (en) 2010-05-13 2013-03-20 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
EP2569299A1 (en) 2010-05-13 2013-03-20 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
WO2011143495A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
CN102947275A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
CA2803358A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012003264A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
MX2012014983A (es) 2010-06-30 2013-04-24 Amgen Inc Quinolinas como inhibidores pi3k.
AU2011272853A1 (en) 2010-07-01 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
JP2013530236A (ja) 2010-07-01 2013-07-25 アムジエン・インコーポレーテツド Ｐｉ３ｋ活性の阻害剤としての複素環式化合物およびその用途
MX2012015134A (es) 2010-07-02 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k.
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
MY150939A (en) 2010-07-13 2014-03-14 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
SI2593452T1 (sl) 2010-07-14 2017-06-30 Novartis Ag Heterociklične spojine agonisti receptorja IP
CA2806108A1 (en) 2010-07-22 2012-01-26 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
BR112013005889A2 (pt) 2010-09-13 2020-08-25 Novartis Ag triazinaoxadiazóis, composição farmacêutica que os compreende e uso dos mesmos
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
ES2610360T3 (es) 2010-09-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Compuestos de imidazotriazinona
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20140031355A1 (en) 2010-11-04 2014-01-30 Amgen Inc. Heterocyclic compounds and their uses
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
AU2011329806A1 (en) 2010-11-17 2013-05-30 Amgen Inc. Quinoline derivatives as PIK3 inhibitors
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US20140039007A1 (en) 2010-12-20 2014-02-06 David C. Tully Compositions and methods for modulating farnesoid x receptors
EP2655368A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
CA2822590A1 (en) 2010-12-23 2012-06-28 Amgen Inc. Heterocyclic compounds and their uses
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
KR20140010031A (ko) 2011-01-13 2014-01-23 노파르티스 아게 대사 장애의 치료를 위한 ｂａｃｅ-2 억제제
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US9321756B2 (en) 2011-03-22 2016-04-26 Amgen Inc. Azole compounds as PIM inhibitors
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
EP2691392A1 (en) 2011-03-31 2014-02-05 EMBLEM Technology Transfer GmbH Imidazo [1,2-a]pyridine compounds for use in therapy
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
MX2013012661A (es) 2011-04-29 2014-03-27 Amgen Inc Compuestos de piridazina biciclicos como inhibidores pim.
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
JP2014530851A (ja) 2011-10-21 2014-11-20 ノバルティスアーゲー Ｐｉ３ｋモジュレータとしてのキナゾリン誘導体
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
WO2013152150A1 (en) 2012-04-04 2013-10-10 Amgen Inc. Heterocyclic compounds and their uses
CA2872000A1 (en) 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof
CN104520291A (zh) 2012-06-06 2015-04-15 Irm责任有限公司 用于调节egfr活性的化合物和组合物
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
ES2584702T3 (es) 2012-06-20 2016-09-28 Novartis Ag Moduladores de ruta del complemento y usos de los mismos
ES2647124T3 (es) 2012-06-28 2017-12-19 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
MX2014015738A (es) 2012-06-28 2015-08-06 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la senda del complemento.
JP6209605B2 (ja) 2012-06-28 2017-10-04 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US20150210717A1 (en) 2012-09-13 2015-07-30 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
CA2980406A1 (en) 2015-03-24 2016-09-29 Helmholtz-Zentrum Fur Infektionsforschung Gmbh 1-deoxy-fucose derivatives as inhibitors of pseudomonas aeruginosa lecb
ES2770128T3 (es) 2015-04-30 2020-06-30 Recordati Ag Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
KR102706357B1 (ko) 2015-08-19 2024-09-11 비버스 인크. 제약 제제
CN105418480B (zh) * 2015-11-16 2019-05-10 青岛大学 2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
WO2017106871A1 (en) 2015-12-18 2017-06-22 Amgen Inc. Alkyl dihydroquinoline sulfonamide compounds
MX2018007511A (es) 2015-12-18 2018-09-18 Amgen Inc Compuestos de alquinil dihidroquinolina sulfonamida.
PL3579874T3 (pl) 2017-02-10 2022-02-28 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pirazol-1-ilo)pirymidyn-2-ylo)-1 h-pirazol-4-ol i jego zastosowanie w leczeniu nowotworu złośliwego
AU2018285449A1 (en) 2017-06-14 2019-12-19 European Molecular Biology Laboratory Benzofuran amides and heteroaromatic analogues thereof for use in therapy
EP3638667A1 (en) 2017-06-14 2020-04-22 European Molecular Biology Laboratory Bicyclic heteroaromatic amide compounds for use in therapy
AU2018285833A1 (en) 2017-06-14 2020-01-02 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
EP3638662A1 (en) 2017-06-14 2020-04-22 European Molecular Biology Laboratory Benzofuran ureas or carbamates and heteroaromatic analogues thereof for use in therapy
US20210038749A1 (en) 2018-02-06 2021-02-11 Universität Heidelberg Fap inhibitor
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
MX2021007156A (es) 2018-12-20 2021-08-16 Amgen Inc Inhibidores de kif18a.
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
US20220002311A1 (en) 2018-12-20 2022-01-06 Amgen Inc. Kif18a inhibitors
MX2022001302A (es) 2019-08-02 2022-03-02 Amgen Inc Inhibidores de kif18a.
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
JP2022542319A (ja) 2019-08-02 2022-09-30 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
CN114901362A (zh) 2019-11-05 2022-08-12 赫姆霍尔兹传染病研究中心有限责任公司 针对铜绿假单胞菌生物膜形成的二价leca抑制剂
CA3163585A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Pharmaceutical compositions and their uses
WO2021148805A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
JP2023521802A (ja) 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤
WO2021234181A1 (en) 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
JP2021195368A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
WO2022043465A1 (en) 2020-08-26 2022-03-03 Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Inhibitors of no production
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
AU2021401426A1 (en) 2020-12-17 2023-06-22 Trustees Of Tufts College Fap-activated radiotheranostics, and uses related thereto
TW202325276A (zh) 2021-10-29 2023-07-01 德商艾斯巴赫生物有限公司 結合至新穎異位結合位之病毒解旋酶抑制劑
TW202348228A (zh) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 病毒組合療法
WO2023213833A1 (en) 2022-05-02 2023-11-09 Eisbach Bio Gmbh Use of alc1 inhibitors and synergy with parpi
WO2024022332A1 (en) 2022-07-26 2024-02-01 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081993A (en) * 1963-04-17 1967-09-06 Ici Ltd Difluoramino compounds
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3417096A (en) * 1965-07-01 1968-12-17 Bristol Myers Co Certain 5(1-benzoyl-3-indolylmethyl) tetrazoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
DK143104C (da) * 1970-09-09 1981-11-09 Ciba Geigy Ag Analogifremgangsmaade til fremstilling af anilinophenylacetamidderivater eller salte deraf
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents

Also Published As

Publication number Publication date
PT72878B (en) 1983-03-29
ES8207508A1 (es) 1982-09-16
ATE14423T1 (de) 1985-08-15
PT72878A (en) 1981-05-01
ES501573A0 (es) 1982-09-16
IE53001B1 (en) 1988-05-11
DK156717B (da) 1989-09-25
JPS56167643A (en) 1981-12-23
EP0039051A2 (en) 1981-11-04
EP0039051B1 (en) 1985-07-24
JPH04982B2 (da) 1992-01-09
IE810899L (en) 1981-10-24
DK156717C (da) 1990-02-19
DE3171467D1 (en) 1985-08-29
GR74496B (da) 1984-06-28
EP0039051A3 (en) 1982-05-26

Similar Documents

Publication Publication Date Title
DK182081A (da) Fremgangsmaade til fremstilling af hydroxaminsyrer
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
PT87277A (pt) Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
IE791490L (en) Phenyl-alkanoic acids
IE780901L (en) Tetrazolyl-piperidinyl amides
MA18964A1 (fr) 2-aminoalkyl-5-pyridinols,procede pour leur preparation,compositions pharmaceutiques contenant ces composes et leurs utilisations therapeutiques
DE3071497D1 (en) 2-penem compounds; a method for their preparation and pharmaceutical compositions comprising them
JPS5589257A (en) New easily-absorbable sulfur-containing prodrug of non- steroidal antiphlogistic, and their drug compositions
ES8105286A1 (es) Un procedimiento para la preparacion de nuevos derivados de dihidropiridina.
GB1434645A (en) Tetrazole coumarin derivatives
DE3063105D1 (en) Clavulanic acid derivatives, process for their preparation and pharmaceutical compositions containing them
GB1080128A (en) Method of producing new nicotinic acid esters

Legal Events

Date Code Title Description
PBP Patent lapsed